Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: zinc finger DNA binding protein transcription factors - Sangamo Therapeutics

Next Previous
X
Search
Drug Profile

Research programme: zinc finger DNA binding protein transcription factors - Sangamo Therapeutics

Alternative Names: AAV-ZFP-VEGF; Ad-ZFP-VEGF; AdV-ZFP-VEGF; ZFP TF ATV; ZFP TF therapeutics - Sangamo

Latest Information Update: 26 Dec 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sangamo BioSciences
  • Developer Sangamo BioSciences; Sangamo Therapeutics
  • Class Gene therapies; Transcription factors; Zinc finger DNA binding proteins
  • Mechanism of Action Genetic transcription modulators; Nav1.8 voltage-gated sodium channel inhibitors; TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Age-related macular degeneration; Alzheimer's disease; Cancer; Neuropathic pain; Parkinson's disease

Highest Development Phases

  • Preclinical Neurological disorders
  • No development reported Neuropathic pain
  • Discontinued Age-related macular degeneration; Cancer

Most Recent Events

  • 26 Dec 2022 Zinc finger DNA binding protein transcription factors is still in preclinical phase for neurological disorders in USA (Sangam Therapeutics website, December 2012)
  • 05 Mar 2020 Preclinical development for Parkinson's disease is ongoing in USA
  • 27 Feb 2020 Biogen enters into a licensing agreement with Sangamo Therapeutics for Neurological diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top